Dendreon vs. CMS: "Full Coverage" or the CED Solution?
This article was originally published in RPM Report
Executive Summary
A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?